PubRank

Marie-Claude Jaurand

Author PubWeight™ 16.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003 1.64
2 Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2004 1.07
3 Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 2011 0.98
4 Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003 0.98
5 Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 2012 0.91
6 Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005 0.89
7 p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 2010 0.88
8 Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 2014 0.86
9 Lectin-based three-color flow cytometric approach for studying cell surface glycosylation changes that occur during apoptosis. Cytometry A 2004 0.82
10 Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol 2011 0.81
11 Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 2004 0.81
12 Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 2002 0.80
13 Biomarkers in risk assessment of asbestos exposure. Mutat Res 2005 0.80
14 Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis 2013 0.79
15 Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol Cancer Ther 2004 0.79
16 Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment. Cancer Genet Cytogenet 2004 0.78
17 Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Lett 2005 0.78
18 Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. Carcinogenesis 2007 0.77
19 Growth, differentiation and senescence of normal human urothelium in an organ-like culture. Eur Urol 2004 0.76
20 [SV40 and cancer: a recurring debate]. Med Sci (Paris) 2003 0.75